长链非编码RNA在胆管癌发生发展中的作用

张世龙; 高伟东; 冯赞杰; 段玉灵; 范国鑫; 彭慈军

doi:10.3969/j.issn.1001-5256.2019.08.054

长链非编码RNA在胆管癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2019.08.054

遵义医科大学附属医院肝胆外科
遵义医科大学生物化学与分子生物学教研室

基金项目:

国家自然科学基金(81660688)；贵州省卫计委基金项目(gzwjkj2016-1-035)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1163
- HTML全文浏览量: 21
- PDF下载量: 231
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-18
- 出版日期: 2019-08-20

Role of long non-coding RNA in the development and progression of cholangiocarcinoma

Department of Hepatobiliary Surgery, The Affiliated Hospital of Zunyi Medical University

Research funding:

摘要

摘要: 胆管癌是起源于胆管上皮细胞的恶性肿瘤,发病率及病死率呈逐年上升趋势,其机制不清使该病早期诊疗困难。随着基因工程学与生物信息学的发展,越来越多的研究发现长链非编码RNA（lncRNA）与胆管癌的病理生理过程密切相关。归纳了近年lncRNA在胆管癌中介导细胞增殖、凋亡、转移、侵袭、上皮-间质转化、耐药等生物学行为及临床特征和预后关系的研究成果。
- 胆管肿瘤 /
- RNA,长链非编码 /
- 病理过程
Abstract: Cholangiocarcinoma is a malignant tumor originating from the epithelial cells of the bile duct, and its incidence and mortality rates keep increasing year by year. Unknown pathogenesis of this disease has led to the difficulties in early diagnosis and treatment. With the development of genetic engineering and bioinformatics, more and more studies have found that long non-coding RNA (lncRNA) is closely associated with the pathophysiological process of cholangiocarcinoma. This article summarizes the research advances in the role of lncRNA in mediating the biological behaviors of cell proliferation, apoptosis, metastasis, invasion, epithelial-mesenchymal transition, and drug resistance in cholangiocarcinoma, as well as the association of lncRNA with clinical features and prognosis.
- bile duct neoplasms /
- RNA, long noncoding /
- pathologic processes

HTML全文

参考文献(31)

[1] BLECHACZ B. Cholangiocarcinoma:Current knowledge and new developments[J]. Gut Liver, 2017, 11 (1) :13-26.

[2] LI JD, XU XF, YU JJ, et al. Updated key points and clinical pathway for NCCN clinical practice guidelines in oncology:Hepatobiliary cancers (Version 1. 2018) [J]. J Clin Hepatol, 2018, 34 (6) :966-977. (in Chinese) 李居东, 徐新飞, 余炯杰, 等.《2018年美国国立综合癌症网络肝胆肿瘤临床实践指南 (V1版) 》更新要点及临床路径[J].临床肝胆病杂志, 2018, 34 (6) :966-977.

[3] DOUSSOT A, JARNAGIN WR, AZOULAY D, et al. Improving actual survival after hepatectomy for intrahepatic cholangiocarcinoma-still a long way to go[J]. Hepatobiliary Surg Nutr, 2019, 8 (2) :161-163.

[4] KAPRANOV P, CHENG J, DIKE S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription[J]. Science, 2007, 316 (5830) :1484-1488.

[5] PONTING CP, OLIVER PL, REIK W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009, 136 (4) :629-641.

[6] SUN M, KRAUS WL. From discovery to function:The expanding roles of long noncoding RNAs in physiology and disease[J]. Endocr Rev, 2015, 36 (1) :25-64.

[7] SORENSEN KP, THOMASSEN M, TAN Q, et al. Long noncoding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer[J]. Breast Cancer Res Treat, 2013, 142 (3) :529-536.

[8] ADELMAN K, EGAN E. Non-coding RNA:More uses for genomic junk[J]. Nature, 2017, 543 (7644) :183-185.

[9] BHAN A, SOLEIMANI M, MANDAL SS. Long noncoding RNA and cancer:A new paradigm[J]. Cancer Res, 2017, 77 (15) :3965-3981.

[10] SUN YS, QU Q, PAN JH, et al. Role of lncRNAs in colorectal cancer[J]. Chin J Clin Pharmacol Ther, 2017, 22 (2) :222-227. (in Chinese) 孙跃胜, 屈强, 潘江华, 等.长链非编码RNA在结直肠癌中的作用[J].中国临床药理学与治疗学, 2017, 22 (2) :222-227.

[11] YANG W, LI Y, SONG X, et al. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing[J].Oncotarget, 2017, 8 (16) :26591-26599.

[12] YU Y, ZHANG M, LIU J, et al. Long non-coding RNA PVT1promotes cell proliferation and migration by silencing ANGPTL4expression in cholangiocarcinoma[J]. Mol Ther Nucleic Acids, 2018, 13:503-513.

[13] YAO Y, SUN Y, JIANG Y, et al. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo[J]. Biomed Pharmacother, 2018, 106:260-266.

[14] LI Y, CAI Q, LI W, et al. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth[J]. Biochem Biophys Res Commun, 2018, 504 (4) :654-659.

[15] VAQUERO J, GUEDJ N, CLAPERON A, et al. Epithelialmesenchymal transition in cholangiocarcinoma:From clinical evidence to regulatory networks[J]. J Hepatology, 2017, 66 (2) :424-441.

[16] XU Y, WANG Z, JIANG X, et al. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition[J]. Biomed Pharmacother, 2017, 92:17-23.

[17] ZHANG SH, XIAO JH, CHAI Y, et al. LncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152[J]. Dig Dis Sci, 2017, 62 (11) :3050-3058.

[18] LU X, ZHOU C, LI R, et al. Long noncoding RNA AFAP1-AS1 promoted tumor growth and invasion in cholangiocarcinoma[J]. Cell Physiol Biochem, 2017, 42 (1) :222-230.

[19] ZHANG C, LI JY, ZHOU FZ, et al. Long noncoding RNA NEAT1 promotes growth and metastasis of cholangiocarcinoma cells[J]. Oncol Res, 2018, 26 (6) :879-888.

[20] LI Z, LI J, JI D, et al. Overexpressed long noncoding RNA Sox2ot predicts poor prognosis for cholangiocarcinoma and promotes cell proliferation and invasion[J]. Gene, 2018, 645:131-136.

[21] QIN X, LU M, ZHOU Y, et al. LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells[J]. Cell Cycle, 2019, 18 (8) :889-897.

[22] KONG L, WU Q, ZHAO L, et al. Upregulated lncRNA-UCA1contributes to metastasis of bile duct carcinoma through regulation of miR-122/CLIC1 and activation of the ERK/MAPK signaling pathway[J]. Cell Cycle, 2019, 18 (11) :1212-1228.

[23] TANG L, WANG Y, WANG H, et al. Lnc-RMRP is involved in the progression of cholangiocarcinoma by regulating miR-217[J]. Cancer Sci, 2019, 110 (7) :2166-2179.

[24] LI J, JIANG X, LI C, et al. LncRNA-MEG3 inhibits cell proliferation and invasion by modulating Bmi1/RNF2 in cholangiocarcinoma[J]. J Cell Physiol, 2019.[Epub ahead of print]

[25] PARASRAMKA M, YAN IK, WANG X, et al. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma[J]. Molecular Cancer, 2017, 16 (1) :22-34.

[26] MA SL, LI AJ, HU ZY, et al. Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma[J]. Mol Med Rep, 2015, 12 (6) :7915-7926.

[27] QIN W, KANG P, XU Y, et al. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma[J]. Sci Rep, 2018, 8 (1) :12176.

[28] ANGENARD G, MERDRIGANC A, LOUIS C, et al. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma[J]. Dig Liver Dis, 2019.[Epub ahead of print]

[29] WANG J, XIE H, LING Q, et al. Coding-noncoding gene expression in intrahepatic cholangiocarcinoma[J]. Transl Res, 2016, 168:107-121.

[30] SU LH, ZHU XY, ZHANG LY. Diagnosis strategies for intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2017, 33 (1) :180-183. (in Chinese) 粟立红, 朱新宇, 张缭云.肝内胆管癌的诊断策略[J].临床肝胆病杂志, 2017, 33 (1) :180-183.

[31] JIANG XM, LI ZL, LI JL, et al. LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma[J]. Eur Rev Med Pharmacol Sci, 2017, 21 (6) :1242-1247.

施引文献

资源附件(0)

访问统计